Filed by Tyco International Ltd.
Pursuant to Rule 425 Under the Securities Act of 1933
Subject Company: Innerdyne, Inc.
Octobor 4, 2000
Innerdyne
Business Segment Overview
-------------------------
<TABLE>
<CAPTION>
----------------------------------------------------------------------------------------------------------------------------
FY99
Sales Business Description Growth Dynamics
----------------------------------------------------------------------------------------------------------------------------
Segments
----------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
1. Laparoscopic Access $20.0 Innerdyne's key product (Step(TM)) Total top line growth:
is an innovative alternative to
using sharp cutting trocars for >> 68% `99 over `98
access during minimally >> Trending in excess of 20% for
invasive surgery (a.k.a. 2000.
"keyhole" surgery"). Step(TM)
uses a principle called radial Future Opportunities:
dilation to gain access, which o Ex-U.S. Vascular Access -
gently separates tissue and product launched this summer via
muscle versus cutting. It Distribution agreement with Maxxim
provides the benefits of Medical (covers U.S. & Latin
enhanced safety, better America. Only).
cosmetics, and less post o Urology - product shown at
surgical pain. last year's AUA. Urological access
using radial dilation.
o Respiratory - radial dilation
Step(TM)has grown, and continues as a means of less traumatic
to grow rapidly. It has been placement of endotracheal tubes.
recognized by Premier - one of o Gastro-Intestinal Medicine -
the US's largest hospital new version of radial dilation
buying groups - as device used for intra-organ access
"Breakthrough Technology" and provides less traumatic means of
as such received the first ever access for surgery on the stomach
contract under Premier's including placement of GI feeding
breakthrough technology tubes.
contracting process.
----------------------------------------------------------------------------------------------------------------------------
2. Biocompatible coatings Not Biocompatible coatings products
research effort Meaning- still in the research phase.
ful Several small licensing
agreements.
----------------------------------------------------------------------------------------------------------------------------
Total: $20.0
----------------------------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
---------------------------------------------------------------------------------------------------------------------------------
FY'99 EBIT
Fit with TYC/Opportunities Margin Highlights/Issues
---------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
1. Laparoscopic Access o Puts USS division in new 6.6% Reinforces Tyco Healthcare's leadership
product area for minimally in development and distribution of
invasive surgical access by clinically beneficial technologies
adding non-bladed access device providing value to patients, surgeons,
to conventional cutting trocars other healthcare providers, and
line. shareholders.
o Tyco Healthcare's
broad-based, global sales
organization will be able to Radial dilation technology platform for
quickly drive this beneficial development of other applications in
technology into the market. minimally invasive surgical and medical
o Creates above market growth procedures.
potential with patented
technology.
------------------------------------------------------------------ ---------------------------------------------------------------
2. Biocompatible coatings Not
research effort Meaningful
------------------------------------------------------------------ ---------------------------------------------------------------
</TABLE>
